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Abstract
Background: Genomic screening has unique challenges which makes it difficult to easily implement on a wide scale.
If the costs, benefits and tradeoffs of investing in genomic screening are not evaluated properly, there is a risk of
wasting finite healthcare resources and also causing avoidable harm.
Main text: If healthcare professionals – including policy makers, payers and providers – wish to incorporate genomic
screening into healthcare while minimizing waste, maximizing benefits, and considering results that matter to patients,
using the principles of triple value (allocative, technical, and personal value) could help them to evaluate tough
decisions and tradeoffs. Allocative value focuses on the optimal distribution of limited healthcare resources to
maximize the health benefits to the entire population while also accounting for all the costs of care delivery. Technical
value ensures that for any given condition, the right intervention is chosen and delivered in the right way. Various
methods (e.g. ACCE, HTA, and Wilson and Jungner screening criteria) exist that can help identify appropriate genomic
applications. Personal value incorporates preference based informed decision making to ensure that patients are
informed about the benefits and harms of the choices available to them and to ensure they make choices based on
their values and preferences.
Conclusions: Using triple value principles can help healthcare professionals make reasoned and tough judgements
about benefits and tradeoffs when they are exploring the role genomic screening for chronic diseases could play in
improving the health of their patients and populations.
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Background
History and hype of genomics
The Human Genome Project began in 1990 with the
goal to map the entire human genome [1]. In April 2003
the project was declared complete and ~ 22,300 genes
were identified with 99.99% accuracy. Although the
function of these genes was not explored in the project,
hopes were high regarding how this new technology
would revolutionise medicine. In retrospect, many ex-
perts claim that there was too much hype surrounding
the topic [2, 3]. In April 2005, 2 years after the Human
Genome Project was completed, a group of international
researchers met for 1 week in Bellagio, Italy, to discuss
how healthcare could benefit from the human genome
[4]. During the meeting various obstacles were identified
that hinder the usage of genomic technology in everyday
clinical practice. For example, most genetic diseases are
polygenic (oligogenic), and thus it is very challenging to
predict if and when these manifest during an individual’s
lifetime [2]. Also, in some instances – such as Hunting-
ton’s disease – the genes associated with the disease can
be identified, but besides preimplantation genetic diag-
nosis to prevent disease manifesting in offspring, at that
time it was considered that no meaningful treatment or
preventive action could be taken [5]. Over a decade has
passed since the meeting and although the cost of
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genomic sequencing has dropped substantially [6], the
same questions of how to bring genomic technology
closer to healthcare and thus, promote personalized
medicine, still remain [7–9].
Although genomic technology is used for various pur-
poses in healthcare, such as pharmacogenomics, this
paper will focus on genomic screening of some specific
subforms of chronic diseases due to the prevalence and
cost associated with these types of diseases. For example,
in the United States about 50% of adults have at least
one chronic disease [10] which accounts for more than
80% of annual health care expenditure [11]. Further to
this, within the realm of genomic applications, the evi-
dence base around using genomic screening for some
monogenic subforms of chronic conditions is relatively
more established than its use for other conditions [12];
for example, the use of cascade screening after finding
index cases has proven clinical utility.
It should be noted in this paper we use the term ‘gen-
omics’, instead of ‘genetics’, to refer to screening for sin-
gle and multiple genes because genomics is a broader
term and techniques may range from single gene testing
and genomic sequencing for analysis of single genes to
techniques utilizing gene panels, such as oncopanels.
The analysis presented in this paper is based on the tar-
geted sequencing and/or analysis of the above-
mentioned monogenic subsets.
Current usage of genomic screening for chronic diseases
Currently, genomic screening is utilized for monogenic
subforms of some common chronic disorders with a
complex etiology typically including gene-gene and
gene-environment interaction. For instance, in cancer
and cardiovascular disorders, genomic screening can be
used for the detection of hereditary breast and ovarian
cancer (HBOC), hereditary forms of colorectal cancer
(CRC), and familial hypercholesterolemia (FH). In such
cases, genomic information is mainly oriented to disease
diagnosis, prognosis and individualised treatment/man-
agement and allows for prevention in family members
[12]. Rather than opting for population screening for
these conditions, cascade screening of first degree family
members of index cases has proven to be (cost) effective
for the aforementioned conditions and is, therefore, rec-
ommended by prominent international bodies. Various
strategies can be applied to identify index patients in-
cluding (combinations of) investigating clinical features
and family history. While several definitions of ‘screen-
ing’ exist, in the context of this paper we focus on (i)
systematic programmatic approaches delivered for (ii)
the benefit of healthy persons. Regarding CRC, the
Evaluation of Genomic Applications in Practice and Pre-
vention (EGAPP) working group (facilitated by the
United States Centers for Disease Control and
Prevention Office of Public Health Genomics) recom-
mends to routinely investigate tumor tissue of all newly
diagnosed CRC cases for markers suggestive of Lynch
syndrome. Genetic testing can be offered to confirm
diagnosis and reduce morbidity and mortality in relatives
through cascade screening and surveillance [13]. A re-
cent systematic review identified examples of structured
and permanent programs of this kind in the USA and
Switzerland [14].
In the case of HBOC, the US Preventive Services
Task Force recommends the use of family history
screening tools by primary care providers to identify
women at increased risk of developing breast cancer
because of harmful mutations. Women with positive
screening results are offered genetic counseling and, if
indicated, offered breast cancer susceptibility genes
(BRCA) testing, in order to reduce morbidity and mor-
tality from breast and ovarian cancer [15]. Programs
of this kind were implemented in various countries,
such as Georgia, Italy (Emilia-Romagna Region) and
Canada (Ontario) [16, 17].
In FH, finding index cases may be based on clinical
symptoms combined with systematically surveying fam-
ily history after which a DNA test can confirm diagnosis.
The UK National Institute for Health and Care Excel-
lence (NICE) recommends cascade (DNA) testing to
identify at-risk relatives of individuals with a genetic
diagnosis of FH [18]. The most famous example of such
a cascade screening program existed in the Netherlands,
where a national government subsidized program was
active between 1994 and 2014 [19].
However, despite progress in the field of genomic
screening for chronic disease, such genomic screening
programs with established evidence bases combining
case finding and cascade screening are not implemented
on a wide scale and there is ambiguity on which tests to
use because the ability to detect a mutation is in itself
not enough to warrant screening [20].
Main text
Exploring genomic screening using triple value principles
Value-based healthcare addresses the question of how to
provide results that matter to patients while optimizing
the usage of limited resources [21–23]. This question
gained even more importance after the 2008 financial
crisis which resulted in austerities within healthcare sys-
tems internationally [24, 25]. Among many responses,
the Triple Value Healthcare principles were introduced
in 2010 and are currently used within the English Na-
tional Health Service (NHS) RightCare Programme, the
Prudent Healthcare Programme in Wales, the Realistic
Medicine Programme in Scotland, the Model of Care in
Saudi Arabia and have also been adopted by an EU
Commission Working Group on value based healthcare
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[26–28]. They adapt Avedis Donabedian’s work and
apply them to universal healthcare systems which have
the two constraints of needing to deliver care to an en-
tire population and doing so within a finite budget, nei-
ther of which are constraints in the US where
Donabedian did most of his work [29]. Triple Value
Healthcare looks at value from three perspectives
(patients, populations and interventions) yielding the
three components of triple value healthcare: (i) Alloca-
tive Value (mostly applicable for policy makers and
payers): ensuring finite resources are allocated to deliver
maximum benefit to the population being served; (ii)
Technical Value (mostly applicable for providers and
payers): ensuring that the interventions being used de-
liver the best outcomes for the resources being utilised;
(iii) Personal Value (mostly applicable for clinicians
within provider organisations): ensuring that patient’s
objective clinical needs and subjective needs are met by
the care they receive. Although these principles were
originally developed for healthcare systems, the princi-
ples are also applicable to broader intervention modal-
ities like genomic screening. In the following sections we
will explore how the Triple Value Healthcare principles
can help healthcare professionals make reasoned and
tough judgements about the role genomic screening for
chronic diseases could play for their patients and
populations.
Allocative value of genomic screening
Every decision regarding the allocation of finite re-
sources that policy makers and payers have to make has
an opportunity cost, which means that every unit of re-
source spent on one area within healthcare is the same
unit of resource that cannot be spent elsewhere. Thus,
when allocating resources, policy makers and payers
must focus on maximizing the health benefits at a popu-
lation level for a given unit of resource while also taking
consideration of those who are most vulnerable in any
given population and who may not be receiving care
[30]. This means that whenever an area of waste – with
waste defined as [31] “spending on services that lack evi-
dence of producing better health outcomes compared to
less-expensive alternatives; inefficiencies in the provision
of health care goods and services; and costs incurred
while treating avoidable medical injuries, such as pre-
ventable infections in hospitals.” – is identified, we must
disinvest from it and use the liberated resources to fund
more beneficial interventions, including innovation. In
the context of genomic screening, one category of inter-
ventions which have questionable benefit and could be
deemed as wasteful are direct to consumer personal gen-
ome testing. As highlighted by McGuire and Burke:
“Similar to other screening tests-or procedures of ques-
tionable clinical value that have been marketed direct-
to-consumer, such as whole body CT scans, ordering
follow-up tests and providing treatment on the basis of
direct-to-consumer personal genome tests of indeter-
minate clinical value constitutes a raid on the medical
commons [32].” It is the responsibility of policy makers,
payers and providers to intervene when interventions
like this put a burden on already limited resources and
also pose a threat by potentially undermining the validity
of genomic screening as a category of intervention in the
minds of patients who are sometimes misled and given
false hopes about what they can achieve.
From a resource allocation perspective, Triple Value
Healthcare principles promote allocation based on the
disease burden within a population rather than on
organizational silos such as primary care or secondary
care (Fig. 1). This approach puts the population’s need
at the forefront of resource allocation decisions and by-
passes political and power struggles that are often times
seen between different healthcare silos.
Once the budget for a disease area is determined, allo-
cation for interventions within the disease area, includ-
ing genomic testing, requires an understanding of the
costs and benefits of the medical interventions currently
available – i.e. technical value. This can be determined
through a variety of methods (see section below on
Technical Value) including using the ACCE (analytic
validity, clinical validity, clinical utility, and ethical, legal,
and social implications) framework, Health Technology
Assessment (HTA) and use of the Wilson and Junger
screening criteria for the available interventions; thus,
giving a standardized method to understand the relative
costs and benefits of available interventions. Further-
more, the entire care pathway costs must be considered
to ensure adequate resources are available to provide the
full complement of care needed.
For genomic disorders, a subset of genes is associated
with multiple diseases (e.g. BRCA 1/2 is associated with
breast and ovarian cancers, Lynch syndrome is generally
associated with a younger age of onset for colorectal,
endometrial and ovarian cancers) so when deciding how
much resource should be spent on breast cancer and
ovarian cancer, for example, some overlaps must be con-
sidered and the two disciplines have to come to agree-
ment on how to fund BRCA 1/2 testing together with
potentially pooled budgets. Furthermore, for genomic
screenings to be meaningful, the follow up procedures
contained with the entire care pathway must be funded
as well – a more valid example, as compared to direct to
consumer personal genomic testing, of needing to draw
from the ‘medical commons’. For example, increased
screening for Lynch syndrome will lead to increased
confirmed cases of mutation carriers and this will also
increase the number of individuals that need follow up
colonoscopies; increased colonoscopies will also increase
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the confirmed cases of colorectal cancers, thus, resulting
in the need for more surgery. This single example high-
lights the challenges health policy makers must consider
when introducing genomic screening into any healthcare
system.
Technical value of genomic screening
It is not enough to only focus on how limited healthcare
resources should be allocated because even if these
resources are distributed optimally, they provide limited
benefits if providers use and payers pay for the wrong
interventions, if the right interventions are not executed
properly by the provider or if the provider delivers the
intervention to the wrong patient. The question of what
factors determine the value of genomic applications has
been debated for a long time and according to recent
literature reviews, the ACCE framework and modified
versions of HTA and the Wilson and Jungner screening
criteria are the most common methods used by the
scientific community to address this question [33, 34].
While the ACCE framework was developed specifically
for the evaluation of genetic tests, the other approaches
were developed to cover health technologies in general
and then adapted or successfully applied to the evalu-
ation of genomic technologies. Below we address the
strengths and weaknesses of these approaches from a
technical value lense.
The original ACCE framework has three components
which are built upon each other while the fourth one
permeates the first three [35]: (i) analytical validity (i.e. a
test’s accuracy and reliability to measure the genotype of
interest); (ii) clinical validity (i.e. how well a test can de-
tect or predict the investigated disorder); (iii) clinical
utility. There is an ongoing debate on how to define
clinical utility. In its narrowest sense, clinical utility is
usually defined as the improvement in health outcomes
due to the test use and subsequent clinical interventions.
Nevertheless, the concept of clinical utility could be ex-
tended to any use of test results to guide the clinical
management of an individual with a diagnosed disorder
or, further, to the improvement of any outcome consid-
ered important to the patients and their families, even if
not strictly health related [36]. Moreover, the ACCE
framework deepens the concept of clinical utility includ-
ing considerations on contextual or implementation
issues, such as cost-effectiveness, education, monitoring
and evaluation. Finally, (iv) an analysis taking ethical,
legal and social issues (ELSI) into account may, for
instance, study effects on family dynamics, psychological
well-being, influence of the test result on lifestyle,
stigmatization, equity of access, and respect for privacy
[37], allowing a weighing of potential harm and waste ver-
sus potential benefits of a genomic test in a specific con-
text. The ACCE model has been adopted and adapted by
various entities since its development, both in the United
States and worldwide. A substantial step in the ACCE’s
evolution came in 2004, when the EGAPP (Evaluation of
Genomic Applications in Practice and Prevention) initia-
tive began to leverage the ACCE model structure and ex-
perience and developed an initiative that supported the
systematic assessment of genetic tests using the ACCE cri-
teria as well as making recommendations for their use in
clinical and public health practice [38].
HTA is a systematic approach for the evaluation of all
health technologies, including genomic tests. Like the
ACCE framework, HTA examines the properties and
effects of a health technology, taking into consideration
scientific, technological, medical, social, legal and ethical
issues [39]. However, the peculiarity of HTA is the great
attention paid to the delivery of a health technology,
reflected by an in-depth analysis of the economic and
organizational aspects related to its implementation [40].
Fig. 1 Illustration of the allocative value within the Triple Value Healthcare principles. The arrows represent the allocation of resources to
lower levels
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An example of HTA applied to the evaluation of gen-
omic technologies is the framework developed by
McMaster University to guide public coverage of new
predictive genetic tests in Ontario [41]. The U.S. Pre-
ventive Services Task Force instead, uses the same HTA
methodology developed for preventive services (i.e.
screening, counselling, and preventive medications) for
evaluating genomic tests [42].
Finally, the Wilson and Jungner screening principles,
developed under the mandate of the World Health
Organization, have been applied to the evaluation of
genetic screening programs; they consider different fac-
tors such as the ability of the test to detect a clinical
condition, the availability of an accepted and effective
treatment, and the cost-effectiveness of the screening
program [33, 43].
Despite having several approaches to assess the
value of specific genomic screening applications, there
is no general agreement on which one should be used
to address the full spectrum of evaluation questions
related to new interventions. Thus, in order for pro-
viders and payers to determine whether to allocate re-
sources to a genomic screening application and to
decide if this reaches the threshold to be worth invest-
ing in, a combination of the ACCE framework, which
is well suited to genetic tests, and the HTA approach,
which addresses important aspects of service delivery,
would be the most adequate strategy based on the
findings thus far [33].
Personal value of genomic screening
Besides the allocation of limited resources and under-
standing the benefits and limitations of genomic applica-
tions, clinicians within provider organisations must also
consider the expectations and values of the patient. To
address this, the Triple Value Healthcare principles em-
phasise both patient satisfaction and the active involve-
ment of the patient through preference-based informed
decision making.
As with any other healthcare services, in order to pro-
vide the best experience for patients, clinicians using
genomic screening should take into consideration the
following eight principles originally proposed by the
Picker Institute: (i) access to care, (ii) respect for pa-
tients’ values, preferences and expressed needs, (iii) co-
ordination and integration of care, (iv) information,
communication and education, (v) physical comfort, (vi)
emotional support and alleviation of fear and anxiety,
(vii) involvement of family and friends, and (viii) con-
tinuity and transition [44, 45]. Beyond these general
principles one must also consider the sensitive nature of
the results derived from genomic testing. Thus, when
communicating results regarding a high risk for a
serious disorder, it is advised that either the genetic
counsellor or other competent health professional gives
this information in person or at least via telephone [46].
Because patients will experience the consequences,
whether good or bad, of any kind of medical interven-
tion, they have a moral right to be involved in the
decision-making process. In addition, taking account of
the needs, preferences and values of the patient could
lead to more optimal use of resources, especially when
unnecessary interventions are avoided. However, due to
the limited resources available, intervention options have
to be constrained within reasonable boundaries. Thus, to
successfully utilize preference-based informed decision
making, three factors are needed: (i) evidence of an in-
tervention’s benefits and harms, (ii) knowledge of the in-
dividuals’ clinical condition and (iii) the values of the
patient [27, 47].
The first factor is encapsulated in Technical Value.
Thus, when there is no proof for the benefit of a gen-
omic application, or if there is reliable proof that this ap-
plication does not meet expectations, then it should not
be offered as an option to the patient.
The second factor would normally only apply for
the patient, however, in genomic screening the condi-
tion of family members, especially first degree rela-
tives in case of dominant disorders, can be related to
that of the index patient. For example, when someone
is diagnosed with breast cancer, a BRCA 1/2 test has
benefit for the index patient because though the dis-
ease is already manifest, it can help in selecting ap-
propriate treatment and interventions and can predict
the probability of the cancer reemerging in the future
[48]. Also, for the individual whose family member
has the BRCA 1/2 mutation or has a family history of
breast cancer, genetic testing for BRCA 1/2 is poten-
tially of high value, since a positive test result may
lead to early surveillance.
Due to the subjective nature of personal values and
preferences, generalizing is challenging but it is pos-
sible for clinicians to identify values and preferences
that can be considered. For example, in the case of
testing for BRCA1/2 related breast cancer, prevention
or health gain would be a valued aim. Planning of
pregnancies and reproductive decisions can also be
based on this information; some prospective parents
may want to reduce the chances of passing a disorder
to the next generation and may opt for prenatal diag-
nosis or preimplantation genetic diagnosis (PGD), de-
pending on their personal values [49]. People that
expect not to benefit from testing for such genetic
disorders can forego testing, for instance because they
prefer not to know and value an open future or
would not be able to cope with the test result. In all
cases, personal values need to be the basis of a
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process of preference based informed decision making
regarding genetic testing.
Value and next generation sequencing
In recent years, the introduction of Next Generation Se-
quencing (NGS) has generated a further complexity in
weighing the pros and cons of genomic screening. The
increased use of sequencing can improve diagnosis, how-
ever, the generation of Secondary Findings (SF) and Var-
iants of Uncertain Significance (VUS) raises ethical, legal
and social issues e.g. regarding consent and use of re-
sources. For example, for cases where clinical sequen-
cing is used, the American College of Medical Genetics
(ACMG) has recommended a deliberate search for SF in
59 genes mostly unrelated to the health problem the pa-
tient presents with [50]. This might be regarded as op-
portunistic screening that optimizes the use of resources
that have already been utilized but critical appraisals
have pointed out that this approach runs counter to
many standard premises in screening [51]. A major
problem related to technical value is the variable evi-
dence related to the different genes, especially regarding
the penetrance and pathogenicity of variants in an un-
affected population. In Europe, the European Society of
Human Genetics (ESHG) has opted for a targeted ap-
proach [52]. After sequencing analysis can be targeted to
the specific genes related to monogenic subforms of
common disorders, such as FH, Lynch syndrome or
BRCA-related breast cancer, similarly limited panels can
be used, such as an onco panel in families where there is
potentially an inherited tumor syndrome.
Professional societies and health authorities are cur-
rently implicated in decisions on which genes and gene
variants to report as SF on specific grounds [53]. For
instance, the French Society of Predictive and Personal-
ized Medicine (SFMPP) elaborated guidelines for man-
aging information on SFs for cancer related genes. “The
main criteria were the ‘actionability’ of the genes (avail-
able screening or prevention strategies), the risk evalu-
ation (severity, penetrance, and age of disease onset),
and the level of evidence from published data” [54].
The selected genes only partially overlapped with the
ACMG oncology genes. While technical value focussing
on the level of evidence is essential, prioritisation based
on, for instance severity and penetrance, as well as on
available resources for analysis, counselling and follow-
up may inform national and local strategies to select
specific subsets of genes in order to allocate resources
proportionally. This typically is relevant in universal
healthcare systems responsible for finite budgets. For
instance in the UK’s 100,000 Genomes Project, a much
more limited set of secondary findings has been se-
lected in genes predisposing to bowel cancer, breast
cancer and FH [55]. To assess allocative value, the
resources devoted for people found to be a carrier of a
mutation in SF without clinical symptoms would have
to be evaluated. Resources spent on this group might
be spent better in, for example, first degree relatives of
BRCA1-carriers who are at 50% risk, while the popula-
tion may be at < 1% risk. In some countries with uni-
versal health care systems, tests not subsidized by the
healthcare service, can be available in the private sector
so that tests with potential personal value to people are
still available. Health authorities should make an effort
to regulate appropriate information provision on the
potential benefits and limitations of such testing to the
public.
Conclusions
Due to the limited resources available and the increasing
need to provide patient-centered care, healthcare as a
whole must strive to reduce waste, maximize benefits
and provide results that matters to patients. Genomic
screening for chronic diseases, as a broad intervention
modality, must also pursue these endeavors. By taking
triple value principles into consideration, healthcare pro-
fessionals, payers and providers can make reasoned and
tough decisions about the role genomic screening for
chronic diseases can play to improve the value of health-
care delivered to their patients and populations.
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